Walleye Trading
ARQT icon

Walleye Trading’s Arcutis Biotherapeutics ARQT Stock Holding History

Walleye Trading’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-916
Closed -$14.4K – 4357
2025
Q2 		$12.8K Buy
+916
New +$12.8K ﹤0.01% 4018
2024
Q1 		– Sell
-12,250
Closed -$39.6K – 4728
2023
Q4 		$39.6K Buy
+12,250
New +$33.3K ﹤0.01% 4385

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Trading's ARQT Position: Q3 2025 in Review

Walleye Trading sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 916 shares — an estimated $14.4K sold.

Walleye Trading first reported a position in ARQT in Q4 2023 and held it in 2 quarters. The position peaked at $39.6K in Q4 2023. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Walleye Trading reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Walleye Trading sold 916 Arcutis Biotherapeutics shares in Q3 2025, an estimated $14.4K.
  • Walleye Trading first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Walleye Trading's Arcutis Biotherapeutics position peaked at $39.6K in Q4 2023.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Walleye Trading's 13F filing for Q3 2025, filed 14 Nov 2025.